Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) and Mounjaro (tirzepatide) both work as injectable weight-loss medications, but they activate different hormonal pathways in your body. Tirzepatide targets two receptors—GLP-1 and GIP—while semaglutide targets only GLP-1, making their effects on hunger, metabolism, and blood sugar distinctly different. Choosing between them depends on how your genetics, body composition, and health history align with each medication's mechanism.
How Semaglutide and Tirzepatide Work Differently
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics a hormone that tells your brain you're full, slows stomach emptying, and improves insulin sensitivity. Tirzepatide is a dual GLP-1/GIP receptor agonist—it activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway simultaneously. This dual action may enhance satiety signals and metabolic rate more robustly than single-pathway activation alone.
The clinical significance of this difference emerged in head-to-head trials. Participants on tirzepatide showed greater average weight loss compared to those on semaglutide at equivalent timepoints, though individual results vary widely. Your genetic makeup influences how efficiently your body responds to each pathway, which is why some patients achieve better outcomes on one medication versus the other.
Weight Loss Results: Semaglutide Versus Tirzepatide
Semaglutide demonstrated an average weight loss of 10–15% of body weight in clinical trials when dosed at the highest maintenance levels. Tirzepatide showed average weight loss ranging from 15–22% depending on the dose tier, with some patients exceeding 25% total body weight reduction. These figures represent averages; individual outcomes depend on adherence, lifestyle factors, and genetic predisposition to peptide signaling.
A key distinction is that tirzepatide's dual mechanism may produce faster initial satiety and potentially greater reduction in metabolic hunger signals. However, semaglutide's longer track record and extensive use in clinical practice provide robust safety data across diverse populations. Neither medication is universally 'better'—the superior choice depends on your personal metabolic profile, tolerance to side effects, and treatment goals.
Genetic Factors That Influence Your Response
Your genes code for GLP-1 receptors, GIP receptors, and other appetite-regulation proteins that determine how effectively you respond to each medication. Variants in GLP1R (rs6923761) and GIPR (rs1800437) directly affect receptor sensitivity and signaling strength. Individuals carrying certain genetic variants may achieve superior weight loss on dual-pathway tirzepatide, while others respond equally well or better to single-pathway semaglutide.
The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Cost, Access, and Treatment Options at PlexusDx
PlexusDx provides compounded semaglutide injection starting at $189/mo (or $149/mo on the 6-month plan) and compounded tirzepatide injection starting at $289/mo (or $249/mo on the 6-month plan)—flat pricing regardless of dose level, because your dose may need to go up but your price won't. Both medications are formulated by licensed 503A compounding pharmacies and shipped to all 50 states without requiring insurance, membership fees, or prior authorization. HSA and FSA accounts cover these compounded therapies, reducing out-of-pocket costs for eligible patients.
For patients seeking dual-pathway benefits without committing solely to tirzepatide, PlexusDx also offers GLP-Squared Injection (a semaglutide and tirzepatide combination) starting at $289/month. Oral versions of both single and dual compounds are available for needle-averse patients. A clinical specialist reviews your health history and genetic profile (if tested) to recommend the protocol most likely to deliver sustained weight loss with manageable side effects.
Side Effects and Tolerability Profiles
Both semaglutide and tirzepatide cause gastrointestinal side effects—nausea, vomiting, diarrhea, and constipation—most pronounced during dose escalation. These effects typically resolve within 1–2 weeks as your body adapts. Tirzepatide's dual mechanism may intensify initial nausea due to stronger satiety signaling, though this does not mean it's unsafe; rather, dose escalation may require a slower titration schedule.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Which Medication Should You Choose?
If your goal is reliable, well-established weight loss with extensive real-world safety data, semaglutide remains an excellent choice, especially for first-time GLP-1 users. If you have moderate-to-severe obesity, type 2 diabetes, or a family history of metabolic dysfunction, tirzepatide's dual-pathway activation may offer superior hunger suppression and glycemic control. Your personal medical history, prior medication responses, and genetic predispositions all inform the optimal selection.
PlexusDx recommends discussing your lifestyle, health conditions, and weight-loss timeline with a clinical specialist to determine whether semaglutide, tirzepatide, or a combination approach best fits your needs. The Precision Peptide Genetic Test provides objective data on your peptide-signaling capacity, enabling evidence-based personalization rather than guesswork. Starting treatment is straightforward: a brief online consultation, baseline labs if needed, and your first dose ships within days.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Is compounded tirzepatide as effective as brand-name Mounjaro?
Compounded tirzepatide from licensed 503A pharmacies contains identical active pharmaceutical ingredient and achieves the same clinical outcomes as brand Mounjaro when dosed properly. The main differences are cost (PlexusDx tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) vs. $900+ for branded) and supply reliability. All PlexusDx formulations undergo sterility and potency testing.
How does the Precision Peptide Genetic Test help me choose?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Which medication causes fewer side effects?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Do I need insurance to start treatment at PlexusDx?
No. PlexusDx serves all 50 states without requiring insurance, prior authorization, or membership fees. Treatment is eligible for HSA/FSA payment. Monthly pricing is transparent and flat—semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan) and tirzepatide injection at $289/mo (or $249/mo on the 6-month plan). Consultations and ongoing clinical support are included.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Treatment: Can You Take Ozempic and Insulin at the Same Time?
When Will Mounjaro Get Approved for Weight Loss?